FY2025 EPS Estimates for Zevra Therapeutics, Inc. Cut by HC Wainwright (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on Monday, August 5th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.26 per share for the year, down from their previous estimate of $0.29. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $3.12 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. The firm had revenue of $3.43 million for the quarter, compared to analyst estimates of $3.52 million.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research note on Monday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $20.25.

Zevra Therapeutics Trading Down 8.1 %

NASDAQ:ZVRA opened at $7.24 on Tuesday. The firm’s fifty day moving average is $5.37 and its 200-day moving average is $5.47. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.10 and a current ratio of 2.10. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.44. The firm has a market cap of $303.02 million, a P/E ratio of -5.36 and a beta of 1.97.

Insider Activity

In other news, Director Thomas Anderson acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, July 16th. The stock was bought at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at $136,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders bought 22,000 shares of company stock worth $140,340. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in shares of Zevra Therapeutics by 17.9% in the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after buying an additional 8,619 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Zevra Therapeutics by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after buying an additional 21,231 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after buying an additional 17,557 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Zevra Therapeutics during the 1st quarter valued at $64,000. Finally, Vanguard Group Inc. raised its position in shares of Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.